ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Monday.

Several other research analysts also recently commented on ZIOP. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, April 6th. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a research note on Thursday, June 1st. They set a “buy” rating and a $9.50 price target on the stock. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $13.00.

Shares of ZIOPHARM Oncology (ZIOP) opened at 5.83 on Monday. The company’s market capitalization is $761.99 million. ZIOPHARM Oncology has a one year low of $4.45 and a one year high of $7.88. The company’s 50 day moving average is $5.92 and its 200 day moving average is $6.34.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.03. The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.71 million. The company’s quarterly revenue was down 18.8% compared to the same quarter last year. Equities research analysts predict that ZIOPHARM Oncology will post ($0.58) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/07/19/ziopharm-oncology-inc-nasdaqziop-stock-rating-upgraded-by-valuengine.html.

Hedge funds have recently added to or reduced their stakes in the stock. Creative Planning raised its position in shares of ZIOPHARM Oncology by 5.2% in the second quarter. Creative Planning now owns 60,863 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 3,000 shares in the last quarter. Teachers Advisors LLC raised its position in shares of ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 3,699 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of ZIOPHARM Oncology by 4.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 88,717 shares of the biotechnology company’s stock valued at $562,000 after buying an additional 3,886 shares in the last quarter. American International Group Inc. raised its position in shares of ZIOPHARM Oncology by 7.1% in the first quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock valued at $475,000 after buying an additional 4,951 shares in the last quarter. Finally, Vident Investment Advisory LLC raised its position in shares of ZIOPHARM Oncology by 5.8% in the fourth quarter. Vident Investment Advisory LLC now owns 114,980 shares of the biotechnology company’s stock valued at $615,000 after buying an additional 6,260 shares in the last quarter. Institutional investors and hedge funds own 38.06% of the company’s stock.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.